Business · 21/01/2026Updated: 10/16/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product KYGEVVI
Summary
The FDA has awarded a priority review voucher to UCB, Inc. for its rare pediatric disease product KYGEVVI, which was approved on November 3, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →